Caroline Stout is a Principal at EcoR1 Capital. She also serves as Chief Investment Officer of Panacea Acquisition Corporation. At EcoR1 Capital, Ms. Stout focuses on investing in private and public biotechnology companies. She has led multiple investments in the cell and gene therapy space. She serves as a Board observer for Accent Therapeutics and Neurogene Inc. Previously, she served as a Board observer for Prevail Therapeutics. Prior to EcoR1, Ms. Stout was a healthcare investment banker at Credit Suisse, where she worked on a variety of transactions across the healthcare and biotechnology sectors. Ms. Stout graduated magna cum laude from Georgetown University with a B.A. in economics.